लोड हो रहा है...

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer

BACKGROUND: Several recent randomized controlled trials (RCTs) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) have demonstrated significant improvements in progression-free survival (PFS); however, few have reported improv...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Breast Cancer (Dove Med Press)
मुख्य लेखकों: Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Tremblay, Gabriel
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Dove Medical Press 2018
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5942170/
https://ncbi.nlm.nih.gov/pubmed/29765247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S162841
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!